DDInter624 DDInter1016
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatitis
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease)
Efavirenz (Compound) binds CYP2C19 (Gene)
Efavirenz (Compound) upregulates IKBKB (Gene)
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Efavirenz (Compound) downregulates POLR2I (Gene)
Efavirenz (Compound) causes Hepatitis (Side Effect)